Latest Litigation News

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.

Big gains hit wealth platforms while Zip swung the other way as early optimism didn’t stick. Dividends and buy-backs kept coming, but investors still punished stocks where the next step looks unclear.

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

London City Equities Limited reported a 38% revenue increase and a $5.6 million capital gain from asset sales, while boosting liquidity to nearly 60% of its portfolio and raising dividends amid a cautious investment outlook.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Transurban Group has reported a robust turnaround in its half-year results to December 2025, with revenue rising 8.1% and profit rebounding from a loss to $343 million. Major infrastructure projects like Melbourne’s West Gate Tunnel and Sydney’s M7-M12 integration are driving growth and operational momentum.

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.

Mayne Pharma has initiated legal proceedings against Cosette Pharmaceuticals and associated parties, seeking substantial damages following the collapse of their acquisition deal.

Fletcher Building reports a stable half-year performance despite subdued markets, advancing its strategic pivot with the announced sale of its Construction division.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Takeover chatter lit up Pepper Money, while Identitii ran hard after a regulator stepped in. At the other end, AMP slid despite higher profit, as investors weighed leadership change and legal costs.